Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2013

GSK Spearheads Cancer Consortium

  • GlaxoSmithKline (GSK) has launched a collaborative scientific research network comprised of six international cancer centers. The newly formed Oncology Clinical and Translational Consortium (OCTC) includes Gustave Roussy, University of Texas MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, Netherlands Cancer Institute, Princess Margaret Cancer Centre, University Health Network, and Vall d’Hebron Institute of Oncology—VHIO.

    In forming the consortium, GSK aims to gain expertise in preclinical, translational, and clinical development of anticancer therapeutics including kinase inhibitors, epigenome modulating compounds, and immunotherapies, which are key areas of focus of GSK’s cancer research drug discovery. The centers will have access to studies with GSK’s early-stage oncology pipeline in an effort to advance the next generation of therapeutics.

    According to GSK, the creation of the consortium emphasizes the company’s commitment to developing innovative patient therapies through rational combination and collaboration with external partners. Projects driven through the OCTC will include Phase I/II single agent and novel combination trials with GSK’s targeted and immune therapies as well as translational and preclinical studies, the company said.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »